NOVOEIGHT

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
NOVOEIGHT
Generic name
ANTIHEMOPHILIC FACTOR RECOMBINANT
Manufacturer
Novo Nordisk
Product type
PLASMA DERIVATIVE
SPL set ID
0a19a631-f494-48ac-8cab-7d572bf7b03d
SPL ID
590d35a4-6e12-450e-9508-0c5bbf2ac427
Version
12
Effective date
2020-07-31
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:54:50

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight and administer appropriate treatment. ( 5.1 ) • Development of activity-neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, are possible with Novoeight. Novoeight contains trace amounts of hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Early signs of hypersensitivity reactions that can progress to anaphylaxis include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if allergic- or anaphylactic-type reactions occur. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of Novoeight. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs [see Adverse Reactions ( 6.1 )] . Monitor all patients for the development of inhibitors by appropriate clinical observation and laboratory testing. If the expected plasma levels of factor VIII activity are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors. 5.3 Monitoring Laboratory Tests • Monitor plasma factor VIII activity levels by the one-stage clotting assay or the chromogenic substrate assay to confirm that adequate factor VIII levels have been achieved and maintained, when clinically indicated. [See Dosage and Administration (2.1) ] • Perform assay to determine if factor VIII inhibitor is present if expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with the expected dose of Novoeight. Determine inhibitor levels in Bethesda Units.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most frequently reported adverse reactions observed in clinical trials (≥ 1%) were injection site reactions, and pyrexia. The most frequently reported adverse reactions (≥ 1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-844-303-4448 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. During the clinical development of Novoeight, 301 male patients (242 previously treated patients (PTPs); exposed to a factor VIII-containing product for ≥150 days and 59 Previously Untreated Patients (PUPs)) with severe hemophilia A (factor VIII level ≤1%) received at least one dose of Novoeight as part of either routine prophylaxis, on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, Immune Tolerance Induction (ITI) or pharmacokinetic evaluation of Novoeight with more than 140,000 exposure days (corresponding to over 900 patient years). During prophylaxis treatment subjects received a median of 468 injections of Novoeight (range 1-1317). Table 4: Summary of Adverse Reactions (ARs ) with a Frequency ≥ 1% in 301 Subjects MedDRA System Organ class Adverse Reactions Frequency N (%) General disorders and administration site conditions Pyrexia 3 (1.0%) Injection site reaction 3 (1.0%) Immunogenicity Subjects were monitored for neutralizing antibodies to factor VIII and binding antibodies to CHO and murine protein. No PTPs developed confirmed neutralizing antibodies to factor VIII. One twenty-two month old previously treated child had a positive neutralizing antibody to factor VIII of 1.3 [BU] in the Bethesda assay after 15 exposure days that was not confirmed when checked after 20 exposure days. In vivo recovery was normal for this child and no clinical adverse findings were observed. In the completed main phase of the clinical trial in PUPs, 24 of 56 (42.9%) patients developed inhibitors with a mean of 14.1 exposure days at the time of the first positive inhibitor test; 15 (26.8%) PUPs developed high titer (≥ 5 BU) inhibitors. High risk genetic mutations were identified in 91.7% of the overall inhibitors and 93.3% of the high titer inhibitors. No patients developed de novo anti-murine antibodies. Nineteen subjects were positive for anti-Chinese hamster ovary (CHO) cell protein antibodies. Two of these subjects changed from anti-CHO negative to anti-CHO positive and 6 subjects changed from anti-CHO positive to anti-CHO negative. The remaining 11 subjects were either positive throughout the trials (n=6), negative at baseline and end-of trial but with transient positive samples (n=2), or positive at baseline and end-of trial but with negative samples in between (n=3). No clinical adverse findings were observed in any of these subjects. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to Novoeight with the incidence of antibodies to other products. 6.2 Postmarketing Experience Adverse reactions reported during post marketing period were similar in nature to those observed during clinical trials.

adverse reactions table

<table width="100%"><col width="37%"/><col width="32%"/><col width="27%"/><tbody><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><list listType="ordered"><item><caption> </caption><content styleCode="bold">MedDRA System Organ class</content></item></list></td><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><list listType="ordered"><item><caption> </caption><content styleCode="bold">Adverse Reactions</content></item></list></td><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><list listType="ordered"><item><caption> </caption><content styleCode="bold">Frequency N (%)</content></item></list></td></tr><tr><td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top"><list listType="ordered"><item><caption> </caption>General disorders and</item><item><caption> </caption>administration site conditions</item></list></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><list listType="ordered"><item><caption> </caption>Pyrexia</item></list></td><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><list listType="ordered"><item><caption> </caption>3 (1.0%)</item></list></td></tr><tr><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><list listType="ordered"><item><caption> </caption>Injection site reaction</item></list></td><td styleCode="Rrule Botrule Lrule Toprule " valign="top"><list listType="ordered"><item><caption> </caption>3 (1.0%)</item></list></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.